Sermorelin vs CJC-1295 is a comparison of two synthetic peptides associated with growth hormone-releasing hormone (GHRH) signalling. Both are studied for their interaction with the GHRH receptor, but their structures, pharmacokinetics and available clinical evidence differ.
Seven Scientific Differences
| Research factor | Sermorelin | CJC-1295 |
|---|---|---|
| 1. Structure | GHRH(1–29) analogue | Modified GHRH analogue |
| 2. Molecular design | Retains the active N-terminal GHRH sequence | Contains substitutions designed to resist degradation |
| 3. Receptor | GHRH receptor agonist | GHRH receptor agonist |
| 4. Persistence | Relatively short-lived | DAC-containing form has prolonged exposure |
| 5. Albumin binding | No DAC modification | DAC form designed for albumin association |
| 6. Human evidence | Historical clinical and diagnostic research | Smaller published human research programme |
| 7. Product identification | Usually identified by peptide sequence | DAC and non-DAC terminology requires clarification |
How Do Their Receptor Mechanisms Compare?
Both peptides act through the GHRH receptor, a G-protein-coupled receptor associated with cyclic AMP signalling and pituitary growth hormone release.
Their shared receptor target does not establish equivalent potency, duration or biological outcomes.
Why the CJC-1295 Form Matters
The term CJC-1295 is sometimes applied inconsistently in research product listings.
The original DAC-containing compound was designed for prolonged exposure through albumin association. Products described as CJC-1295 without DAC should not automatically be assigned the same pharmacokinetic properties.
Laboratories should confirm the exact sequence, molecular mass and compound identity before comparing results.
What Does Human Research Establish?
Published human research on DAC-containing CJC-1295 reported sustained changes in growth hormone and IGF-1 measurements.
Sermorelin has a longer history of clinical research involving GHRH-related endocrine responses.
Neither evidence base establishes that the compounds are interchangeable or appropriate for unsupervised human use.
For purchasing documentation, see our research peptide supplier enquiry template.
Peptide Lab Direct UK is a UK research peptide website.
Frequently Asked Questions
1. Are sermorelin and CJC-1295 identical?
No. Their molecular structures differ.
2. Do both target GHRH receptors?
Yes, although their pharmacokinetics differ.
3. Does every CJC-1295 product contain DAC?
No. Confirm the exact compound.
4. Which has longer documented exposure?
DAC-containing CJC-1295.
5. Does longer exposure prove greater effectiveness?
No. Exposure and efficacy are different measures.
6. Can one compound’s COA verify the other?
No. Identity testing must match the material.
Conclusion
The central distinction in sermorelin vs CJC-1295 research is not receptor selection alone. Molecular modification, exposure duration and the identity of the CJC-1295 formulation are essential to interpreting scientific findings.
For laboratory research only. Not intended for human administration or clinical use.
Scientific References
- Mayo KE et al. International Union of Pharmacology: Growth Hormone-Releasing Hormone Receptors. Pharmacological Reviews. https://pubmed.ncbi.nlm.nih.gov/?term=growth+hormone+releasing+hormone+receptor+pharmacological+reviews
- Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. JCEM, 2006. https://pubmed.ncbi.nlm.nih.gov/?term=Teichman+CJC-1295+2006
- Historical sermorelin clinical literature: https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+growth+hormone+releasing+hormone
2 comments